OSL 15.4% 1.5¢ oncosil medical ltd

Ann: OncoSil AGM CEO Presentation, page-96

  1. Al.
    198 Posts.
    lightbulb Created with Sketch. 114
    'Pancreatic Cancer Deaths IncreasingThese recent treatment advances are long overdue. Although deaths from most malignancies are declining, pancreatic cancer moved from the fourth leading cause of cancer death to the third in 2016, surpassing breast cancer. The population is growing older and living longer, and innovative new therapies have largely passed this tumor by, Dr. Tempero said. The vast majority of patients with pancreatic cancer are diagnosed with advanced unresectable disease; most patients experience relapse after treatment. Furthermore, the “cure rate” for this disease is only 9%, and without treatment, the median survival of patients with metastatic disease is only 3 months.“This is a very tough disease,” Dr. Tempero noted. “There are no early symptoms, the tumor invades and metastasizes early, it is somewhat chemotherapy-resistant, and patients suffer from debilitating cytokine-mediated symptoms.' https://jnccn.org/view/journals/jnccn/17/5.5/article-p603.xml
 
watchlist Created with Sketch. Add OSL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.